A.V. Gaponiuk

A.V. Gaponiuk

Auto-generated profile, based on publicly available information

A.V. Gaponiuk

Saqr Hospital, Ras Al Khaimah, United Arab Emirates

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2025 in Infusion & Chemotherapy
Verified
Journal Article
Open access
PDF file
SZS.V. Zaikov
S.V. Zaikov
АBА.YE. Bоgomоlоv
А.YE. Bоgomоlоv
MLM.A. Lykova
M.A. Lykova
AGA.V. Gaponiuk
A.V. Gaponiuk
BACKGROUND. Cholinergic urticaria occupies a significant place in the structure of chronic urticaria. This problem is particularly relevant for young men leading an active lifestyle. For this and other age groups, the presence of cholinergic urticaria poses a serious risk of systemic anaphylactic reactions in cases of professional sports or intensive physical training. OBJECTIVE. To analyze available data on the etiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prevention of cholinergic urticaria. MATERIALS AND METHODS. A search for available information sources, analytical processing, and discussion of the obtained results. RESULTS AND DISCUSSION. The diagnosis of cholinergic urticaria is based on thorough history taking and the use of provocation and laboratory tests. However, the episodic nature of symptoms and the lack of physician awareness about this form of urticaria often lead to prolonged delays in diagnosis and treatment initiation. Without adequate control, cholinergic urticaria significantly impairs quality of life, daily activities, and is associated with substantial costs, while concomitant angioedema and anaphylaxis may pose a life-threatening risk. Differential diagnosis may be challenging between cholinergic urticaria with angioedema, exercise-induced urticaria, and exercise-induced anaphylaxis associated with a food trigger, most commonly wheat allergen ω5-gliadin. In exercise-induced anaphylaxis, the potential risk lies in the physical activity itself, whereas in cholinergic urticaria, any situation associated with increased sweating – including medical interventions – may provoke a systemic reaction. Treatment of patients with cholinergic urticaria is based on a stepwise approach, depending on disease severity and treatment response. First-line therapy consists of second-generation antihistamines. In the absence of adequate response, further treatment should be individualized, taking into account disease severity, endotype, predictors of therapy response, patient’s individual characteristics, comorbidities, and pharmacological properties of recommended medications. Useful agents for the treatment of patients with cholinergic urticaria may include drugs containing belladonna extract and atropine, which act by suppressing acetylcholine activity. CONCLUSIONS. It is necessary to draw the attention of the medical community to the challenges of diagnosing cholinergic urticaria, the importance of further investigation of its biomarkers, informing patients about the necessity of provocation testing, the use of validated questionnaires in clinical evaluation, as well as formulating recommendations on lifestyle modification for individuals with cholinergic urticaria and on specific aspects of performing medical interventions in such patients. The management of cholinergic urticaria requires further research.

23 December 2025 in Infusion & Chemotherapy
Verified
Journal Article
Open access
SZS.V. Zaikov
S.V. Zaikov
MLM.A. Lykova
M.A. Lykova
TKT.V. Kyrylenko
T.V. Kyrylenko
EDE.M. Dmytriieva
E.M. Dmytriieva
AGA.V. Gaponiuk
A.V. Gaponiuk
BACKGROUND. Vasomotor rhinitis represents a significant global health burden, with prevalence rates ranging from 5 to 25 %. It is a subtype of non-allergic rhinitis, a heterogeneous group of disorders characterized by rhinitis symptoms not caused by atopy or infection, which are sometimes grouped with other phenotypes such as gustatory, hormonal, or drug-induced rhinitis. In contrast to allergic rhinitis, which involves IgE-mediated immune responses, vasomotor rhinitis is driven by neurogenic and autonomic dysfunction. Previously, several authors proposed using the terms “vasomotor rhinitis” and “non-allergic rhinopathy” concurrently, or even classifying allergic rhinitis under vasomotor rhinitis. This creates discrepancies in interpreting the concepts of “vasomotor rhinitis”, “non-allergic rhinopathy”, and “allergic rhinitis”, hindering a clear understanding of management approaches for the respective patient categories. OBJECTIVE. To analyze available data on the etiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prevention of vasomotor rhinitis. MATERIALS AND METHODS. A search for available information sources, analytical processing, and discussion of the obtained results. RESULTS AND DISCUSSION. Vasomotor rhinitis is a common, yet poorly studied, type of chronic rhinitis that is currently believed to be neurogenic in origin. Several authors use the term “non-allergic rhinopathy” instead of “vasomotor rhinitis”, which complicates the understanding of this issue. Currently, there are no unified international diagnostic criteria for vasomotor rhinitis. In real clinical practice, physicians should perform differential diagnosis between vasomotor and allergic rhinitis (using specific allergodiagnostic methods), as well as exclude infectious rhinitis, drug-induced rhinitis, and chronic rhinosinusitis (using history taking, endoscopy, and other supplementary investigation methods). The majority of patients with vasomotor rhinitis respond adequately to treatment with topical saline solutions, topical antihistamines, corticosteroids, and ipratropium sprays, all of which alleviate rhinitis symptoms. Individuals who are refractory to traditional treatment may undergo therapy with capsaicin, botulinum toxin, and posterior nasal nerve ablation using radiofrequency ablation or cryotherapy. Currently, biological agents and neuromodulatory treatments are at various stages of investigation, focusing on the effect of such targeted therapy on type 2 inflammation, specifically the blockade of interleukin-4 and -13. Despite the encouraging nature of this data for other rhinitis subtypes, their role in vasomotor rhinitis remains unclear. Standardized and highly agreed-upon diagnostic criteria for vasomotor rhinitis must be developed to allow for more precise patient classification through phenotyping, enable targeted therapeutic selection, and establish a reliable evidence base regarding the efficacy and safety of treatment methods for this patient category. CONCLUSIONS. Patients with vasomotor rhinitis often seek medical attention from allergists, otolaryngologists, and physicians of other specialties. Currently, there is no standardized approach to the management of such patients among various specialists. The issue of vasomotor rhinitis remains relevant and poorly understood, but the approaches to managing these patients must be unified.

1 January 2025 in OTORHINOLARYNGOLOGY
Verified
Journal Article
Closed access
SPSergey Pukhlik
Sergey Pukhlik
OTOlga Titarenko
Olga Titarenko
IDIryna Diedykova
Iryna Diedykova
AGAndriy Gaponyuk
Andriy Gaponyuk
Topicality: Definitions provide shared knowledge and a common understanding of a topic. Agreed terminology is essential for communication and interconnected activities. This is important when we talk, write, or read about science. By providing either an unambiguous description of the phenomenon or a reasonable interpretation of its underlying causes, each definition should allow for the clear identification and classification of referent objects. Current terms describing olfactory dysfunction are vague and overlapping. Objective: In order to clearly and unambiguously define and interpret the most common terms related to smell, namely: dysosmia, anosmia, hyposmia, normosmia, hyperosmia, olfactory intolerance, parosmia, and phantosmia (also known as "olfactory hallucination"), we wrote this article for Ukrainian doctors and scientists. This will allow authors and readers of olfaction-related literature to have a common understanding of what is meant when these terms are used. Results: Quantitative olfactory function is often associated with terms related to quantitative olfactory dysfunction (i.e., "anosmia," "hyposmia," and "normosmia"). The word "subjective" refers to a person's self-assessment of olfactory function. Qualitative olfactory dysfunction (i.e., parosmia, phantosmia) is often considered “subjective,” given that validated psychophysical tests to assess these conditions are currently unavailable. However, the word “subjective” can also be added to quantitative terms (i.e., anosmia, hyposmia, or normosmia) to denote a self-reported olfactory function or dysfunction that is not confirmed by psychophysical olfactory testing. Although measured olfactory function is often the basis for treatment of patients with olfactory complaints, subjective olfactory function may sometimes better reflect quality of life. Conclusions: We propose standardizing the use of the terms "dysosmia", "anosmia", "hyposmia", "normosmia", "hyperosmia", "olfactory intolerance", "parosmia" and "phantosmia" or "olfactory hallucinations" in communication related to smell. Further clarification of whether olfactory function is “measured” or “subjective” is useful in clinical settings. The precise use of these terms will improve scientific communication in a field that is poised to continue to evolve. Keywords: dysosmia, anosmia, hyposmia, normosmia, hyperosmia, olfactory intolerance, parosmia, phantosmia, cacosmia, olfactory tests.